Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions
At 42:10 · chapter starts 41:45
A sophisticated counterargument arises with gray-market GLP-1 agonists: if the molecule is proven, doesn't a copy with the same sequence benefit from that evidence? Peter argues this reflects a fundamental misunderstanding of what a pharmaceutical product actually is. Using retatrutide as an example, he walks through the enormous engineering and manufacturing challenges that must be solved beyond simply assembling the right amino acids: reproducible manufacturing at scale, consistent purification, batch-to-batch analytical equivalence. [1] — Peter Attia "A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency…" 41:50 A pharmaceutical is the successful solution to all of those problems, not just a molecular structure. When a clinical trial demonstrates efficacy, it validates a specific product manufactured under specific processes with specific physicochemical characteristics — not an abstract amino acid sequence. Two vials claiming the same sequence may differ in clinically important ways. This isn't primarily a regulatory argument; it's a chemistry and manufacturing reality.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
